dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Chumsri, Saranya |
dc.contributor.author | Li, Zhuo |
dc.contributor.author | Serie, Daniel J. |
dc.contributor.author | Norton, Nadine |
dc.contributor.author | Mashadi-Hossein, Afshin |
dc.contributor.author | Tenner, Kathleen |
dc.contributor.author | Saura Manich, Cristina |
dc.date.accessioned | 2022-09-07T12:08:48Z |
dc.date.available | 2022-09-07T12:08:48Z |
dc.date.issued | 2022-05-24 |
dc.identifier.citation | Chumsri S, Li Z, Serie DJ, Norton N, Mashadi-Hossein A, Tenner K, et al. Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. NPJ Breast Cancer. 2022 May 24;8:68. |
dc.identifier.issn | 1662-453X |
dc.identifier.uri | https://hdl.handle.net/11351/8055 |
dc.description | Càncer de mama; Marcadors predictius |
dc.description.sponsorship | Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180882 and U24CA196171 (to the Alliance for Clinical Trials in Oncology); UG1CA233180, UG1CA232760, UG1CA233373, and U10CA180821. https://acknowledgments.alliancefound.org. Also supported in part by funds from the Department of Defense W81XWH-18-1-0562 and −0563 and W81XWH-16-1-0265 and 0266, as well as the Breast Cancer Research Foundation (BCRF-19-161), Bankhead-Coley Research Program (6BC05), Susan G. Komen Foundation (SAC190091), and the DONNA Foundation. The content is solely the authors’ responsibility and does not necessarily represent the official views of the National Institutes of Health. Genentech/Roche supplied trastuzumab for both trials. Presented at the Spotlight Session at San Antonio Breast Cancer Symposium 2016 and the ASCO Annual Meeting 2018. Portions of this paper have been published in abstract form: Journal of Clinical Oncology 36, no. 15_suppl (May 20, 2018) 577. |
dc.language.iso | eng |
dc.publisher | Nature Research |
dc.relation.ispartofseries | NPJ Breast Cancer;8 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Expressió gènica |
dc.subject | Resposta immunitària |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Gene Expression Regulation, Neoplastic |
dc.subject.mesh | Dose-Response Relationship, Immunologic |
dc.title | Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41523-022-00430-0 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | regulación de la expresión génica neoplásica |
dc.subject.decs | relación dosis-respuesta inmunológica |
dc.relation.publishversion | https://doi.org/10.1038/s41523-022-00430-0 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Chumsri S] Jacoby Center for Breast Health, Mayo Clinic, Jacksonville, FL, USA. [Li Z, Serie DJ] Department of Health and Human Services, Mayo Clinic, Jacksonville, FL, USA. [Norton N] Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA. [Mashadi-Hossein A] NanoString, Inc., Seattle, WA, USA. [Tenner K] Department of Health and Human Services, Mayo Clinic, Rochester, MN, USA. [Saura C] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain |
dc.identifier.pmid | 35610260 |
dc.identifier.wos | 000799816800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |